35 results on '"Bertolini, F."'
Search Results
2. 1124P Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
3. 1349P A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)
4. 147P Chemo-immunotherapy with or without consolidative radiotherapy in extensive-stage small cell lung cancer: An initial report of clinical outcome and safety
5. Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer
6. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
7. 2003P Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
8. 1994P Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
9. P-96 Circulating tumor-derived DNA (ctDNA) clearance in patients with locally advanced rectal cancer treated with multimodal treatment
10. Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study
11. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
12. Locoregional recurrence risk after lipofilling in breast cancer patients
13. 1815MO Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial
14. 953P Sarcopenia as predictive factor of response to nivolumab in recurrent-metastatic head and neck (RM-SCCHN) cancer patients
15. Short- and long-term safety of the 2 × 106 CD34+ cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support
16. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
17. Maspin, a recently discovered antiangiogenesis tumor suppressor gene, protects micrometastatic breast cancer patients from relapse.
18. Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and mismatch-repair proteins expression in malignant mesothelioma
19. Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): Preliminary results
20. Incidence and survival of secondary malignances (SM) in oropharingeal squamous cell carcinoma (OPSCC): A homogeneous single report institution
21. 1808P - Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and mismatch-repair proteins expression in malignant mesothelioma
22. P-300 - Predictive value of circulating tumor-derived DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CT-RT): Preliminary results
23. Pleuro-pulmonary synovial sarcoma: clinico-pathologic and molecular characteristics from a multi-institutional series of 48 cases
24. The phase III study INTERCEPTOR in locally advanced head and neck cancer (LA-HNC). Preliminary safety report
25. Mutational analysis of EGFR, c-KIT, PDGFRs, BRAF and KRAS, and expression of ALK and PD-L1 in a series of 103 thymic epithelial tumors with different histology
26. Multidisciplinary approach for squamous head and neck cancers: a single report institution
27. Immunohistochemistry (IHC) analysis with 3 different antibodies (Abs) and thymidylate synthase (TS) evaluation of FISH-positive ALK-rearranged (ALK+) lung adenocarcinomas (ADK)
28. The role of the activation of mTOR pathway in patients with advanced neuroendocrine tumors treated with everolimus
29. 1104P - Incidence and survival of secondary malignances (SM) in oropharingeal squamous cell carcinoma (OPSCC): A homogeneous single report institution
30. A Phase Ib Study of Everolimus, 5-Fluorouracil (5-Fu) and Pelvic Radiotherapy (Rt) As Neo-Adjuvant Treatment for Locally Advanced Rectal Cancer (Larc)
31. Gene Expression Analysis of Triple Negative Recurrent Lymphangitic Breast Cancer in Patients Receiving Antiangiogenic Therapy
32. Multiple Myeloma and Related Disorders
33. 591P - A Phase Ib Study of Everolimus, 5-Fluorouracil (5-Fu) and Pelvic Radiotherapy (Rt) As Neo-Adjuvant Treatment for Locally Advanced Rectal Cancer (Larc)
34. 36P - Gene Expression Analysis of Triple Negative Recurrent Lymphangitic Breast Cancer in Patients Receiving Antiangiogenic Therapy
35. Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.